These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16506919)

  • 1. Phase I trial and pharmacokinetic analysis of ifosfamide in cats with sarcomas.
    Rassnick KM; Moore AS; Northrup NC; Kristal O; Beaulieu BB; Lewis LD; Page RL
    Am J Vet Res; 2006 Mar; 67(3):510-6. PubMed ID: 16506919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a phase II clinical trial on the use of ifosfamide for treatment of cats with vaccine-associated sarcomas.
    Rassnick KM; Rodriguez CO; Khanna C; Rosenberg MP; Kristal O; Chaffin K; Page RL
    Am J Vet Res; 2006 Mar; 67(3):517-23. PubMed ID: 16506920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical evaluation of carboplatin in tumor-bearing cats: a Veterinary Cooperative Oncology Group study.
    Kisseberth WC; Vail DM; Yaissle J; Jeglum KA; Couto CG; Ward H; Khanna C; Obradovich JE
    J Vet Intern Med; 2008; 22(1):83-8. PubMed ID: 18289293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ifosfamide in the treatment of soft tissue sarcomas.
    Connelly EF; Budd GT
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):16-21. PubMed ID: 8677442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lomustine for treatment of mast cell tumors in cats: 38 cases (1999-2005).
    Rassnick KM; Williams LE; Kristal O; Al-Sarraf R; Baez JL; Zwahlen CH; Dank G
    J Am Vet Med Assoc; 2008 Apr; 232(8):1200-5. PubMed ID: 18412534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematologic and systemic toxicoses associated with carboplatin administration in cats.
    Hahn KA; McEntee MF; Daniel GB; Legendre AM; Nolan ML
    Am J Vet Res; 1997 Jun; 58(6):677-9. PubMed ID: 9185979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
    Nielsen OS; Reichardt P; Christensen TB; Pink D; Daugaard S; Hermans C; Marreaud S; van Glabbeke M; Blay J; Judson I
    Eur J Cancer; 2006 Sep; 42(14):2303-9. PubMed ID: 16891112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosage escalation of intravenous cyclophosphamide in cats with cancer.
    Moore AS; Frimberger AE; Chan CM
    Vet J; 2018 Dec; 242():39-43. PubMed ID: 30503542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of a 24-h continuous infusion of ifosfamide/mesna in acute lymphoblastic leukemia.
    Otero JC; Solidoro A; Casanova L; Vallejos C; Rodriguez W
    J Exp Ther Oncol; 1996 Mar; 1(2):84-7. PubMed ID: 9414391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
    Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [High-dose ifosfamide in the treatment of patients with soft tissue sarcoma].
    Tiuliandin SA; Liubimova NV; Sidorova NI; Averinova SG; Kashkadaeva AV; Romanova LF; Shiriaev SV; Garin AM
    Vopr Onkol; 1996; 42(6):19-22. PubMed ID: 9123896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione.
    Pendyala L; Creaven PJ; Schwartz G; Meropol NJ; Bolanowska-Higdon W; Zdanowicz J; Murphy M; Perez R
    Clin Cancer Res; 2000 Apr; 6(4):1314-21. PubMed ID: 10778956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical trial of vinorelbine in tumor-bearing cats.
    Pierro JA; Mallett CL; Saba CF
    J Vet Intern Med; 2013; 27(4):943-8. PubMed ID: 23662626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
    Mace JR; Keohan ML; Bernardy H; Junge K; Niebch G; Romeis P; Thoma A; Wagner T; Mueller U; Demetri G; Baker LH
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5829-34. PubMed ID: 14676103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicoses and efficacy associated with administration of mitoxantrone to cats with malignant tumors.
    Ogilvie GK; Moore AS; Obradovich JE; Elmslie RE; Vail DM; Straw RC; Salmon MD; Klein MK; Atwater SW; Ciekot PE
    J Am Vet Med Assoc; 1993 Jun; 202(11):1839-44. PubMed ID: 8320152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
    J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.
    Mita AC; Denis LJ; Rowinsky EK; Debono JS; Goetz AD; Ochoa L; Forouzesh B; Beeram M; Patnaik A; Molpus K; Semiond D; Besenval M; Tolcher AW
    Clin Cancer Res; 2009 Jan; 15(2):723-30. PubMed ID: 19147780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and bioavailability of stereoisomeric analogues of ifosfamide.
    Sloderbach A; Hładoń B; Laskowska H
    Acta Physiol Hung; 1996; 84(4):459-60. PubMed ID: 9328631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer.
    Horti J; Juhasz E; Monostori Z; Maeda K; Eckhardt S; Bodrogi I
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):173-80. PubMed ID: 18214483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.
    Maurel J; López-Pousa A; de Las Peñas R; Fra J; Martín J; Cruz J; Casado A; Poveda A; Martínez-Trufero J; Balañá C; Gómez MA; Cubedo R; Gallego O; Rubio-Viqueira B; Rubió J; Andrés R; Sevilla I; de la Cruz JJ; Del Muro XG; Buesa JM
    J Clin Oncol; 2009 Apr; 27(11):1893-8. PubMed ID: 19273704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.